About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Global Congress on Prostate Cancer - PROSCA 2019
prosca.org
Diagnosing Prostate Cancer
Chemotherapy in High-Risk Localized PC & mCRPC
Metastatic Hormone-Sensitive Prostate Cancer
Cardiovascular-Related Events
CRPC in Clinical Practice
APCCC 2019 Expert Recommendations
Localized Prostate Cancer
Biochemical Recurrence After Radical Therapy
The Prostate Cancer Challenge
Oligometastatic Prostate Cancer
High-Risk nmPC
Best Poster Session
Biomarkers in mPC
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
K
To Treat or Not to Treat Non-Metastatic Castration Resistant Prostate Cancer: Effectiveness and Safety Profile of Darolutamide, Enzalutamide, and Apalutamide
By
Global Congress on Prostate Cancer - PROSCA 2019
FEATURING
Karim Fizazi
By
Global Congress on Prostate Cancer - PROSCA 2019
FEATURING
Karim Fizazi
273 views
December 31, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
20:25
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Featured Video
20:59
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
CRPC in Clinical Practice
19:14
Global Congress on Prostate Cancer - PROSCA 2019
To Treat or Not to Treat Non-Metastatic Castration Resistant Prostat…
Feat.
K. Fizazi
20:43
Global Congress on Prostate Cancer - PROSCA 2019
Early Enzalutamide, Apalutamide, or Abiraterone Are the New Standard…
Feat.
B. Tombal
21:24
Global Congress on Prostate Cancer - PROSCA 2019
New Agents in mCRPC: PARPi Should Have Role for DDR-Deficient Disease
Feat.
P. Grivas
